Jawitz OK, Stebbins AS, Raman V, et al. - Researchers assessed the link between levosimendan therapy and acute kidney injury (AKI) and also examined the clinical sequelae of AKI among cardiac surgery patients with depressed left ventricular function (ejection fraction < 35%). Based on occurrence as well as severity of postoperative AKI, stratification of patients in the LEVO-CTS trial receiving on-pump coronary artery bypass grafting (CABG), valve, or CABG/valve surgery was performed. Employing multivariable regression, experts modeled the link between levosimendan infusion and AKI. Patients receiving levosimendan or placebo were found to have a similar rate of AKI. The odds of 30-day death significantly rose by AKI stage vs those without AKI. Findings showed that high-risk patients undergoing cardiac surgery commonly developed postoperative AKI, and that the occurrence of postoperative AKI was related to significantly raised risk of 30-day death or dialysis. There was no link of levosimendan with the risk of AKI.